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aged 50 and older: a review
Renske Eilers1,2*, Paul FM Krabbe1, Ted GA van Essen3, Anita Suijkerbuijk4, Alies van Lier2 and Hester E de Melker2Abstract
Background: The increasing life expectancy in most European countries has resulted in growth of the population
50 and older. This population is more susceptible to infectious diseases because of immunosenescence, co-
morbidity and general frailty. Thus, to promote healthy aging, vaccination against vaccine-preventable-diseases
could be one strategy. In addition to its possible individual benefits, vaccination may also yield social benefits,
such as a lower overall cost of healthcare. Most European countries, however, offer only influenza vaccine although
vaccines for pneumococcal disease, herpes zoster, pertussis, and hepatitis A are also available. Our aim is to review
the knowledge of these vaccines for persons aged 50 and older and explore the arguments for expanding current
vaccination programmes beyond just influenza.
Methods: The evaluation model of Kimman et al. was used to assess herpes zoster, pneumococcal disease,
pertussis and hepatitis A in terms of four domains: pathogen, vaccine, disease outcomes and cost-effectiveness.
The sources were Dutch surveillance systems, seroprevalence studies and the international literature.
Results: Herpes zoster, pneumococcal disease and pertussis are prevalent among persons aged 50 and older.
Vaccines vary in effectiveness and have mild and self-limiting side effects. Vaccination against pneumococcal
disease and pertussis causes adaptation of the responsible pathogen. For pertussis and hepatitis A, the vaccine is
not registered specifically for the elderly population. Vaccination against herpes zoster and pertussis could improve
quality of life, while vaccination against pneumococcal disease and hepatitis A prevents mortality. However, only
vaccination against herpes zoster and pneumococcal disease appear to be cost-effective.
Conclusions: Vaccination can improve the health of the elderly population. As our review shows, however, the
data are too incomplete to accurately judge its potential impact. More research is needed to determine how
vaccination can most effectively improve the health of the growing population 50 years and older.
Keywords: Older persons, Vaccination, Vaccines, Herpes zoster, Pneumococcal disease, Pertussis, Hepatitis ABackground
The increasing life expectancy in most European
countries has resulted in the growth of the population
50 and older. Although this population will continue to
increase, it may not age healthily [1,2]. It is estimated
that by 2060, persons aged 65 and older will account for
30.0% of the total population of the EU-27 (the 27 Mem-
ber States of the European Union), compared to 17.0%
in 2008 [3].* Correspondence: renske.eilers@rivm.nl
1Department of Epidemiology, University of Groningen, Academic Medical
Center Groningen, P.O. Box 30.001, Groningen 9700 RB, The Netherlands
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reproduction in any medium, provided the orAs a result of immunosenescence (the gradual deteri-
oration of the immune system), co-morbidity and
general frailty, this population is more susceptible than
younger persons to infectious diseases [4], resulting in
higher mortality and morbidity rates in older persons
than in young adults [5]. Infections may lead to irrevers-
ible frailty and, thereby, more dependency on long-term
healthcare [6]. Vaccinating persons aged 50 and older
against vaccine-preventable diseases (VPDs) may be one
strategy to promote healthy aging.
Apart from possible benefits to individuals in this
age group, vaccination may yield social benefits, such
as lower overall costs of European healthcare. Most
European countries offer influenza vaccine to thisd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cal vaccine [7]. However, vaccination against other
VPDs is not common, despite initiatives to update the
programmes [8].
The aim of this review is to evaluate the vaccines
available for persons aged 50 and older and to explore
the arguments of programmatic vaccination for herpes
zoster, pneumococcal disease, pertussis and hepatitis
A. For each of these infectious diseases, we review the
current knowledge of these vaccines as specifically
applied to this population and describe each of four
domains (pathogen, vaccine, disease and cost effective-
ness), according to the model of Kimman et al. [9].
Rationale for vaccine choice
Herpes zoster, pneumococcal disease, pertussis and
hepatitis A were chosen for this review because a vac-
cine for each is registered in Europe. Furthermore, a re-
port by the Dutch health council on the future of the
national immunization programme focused on the possi-
bility of persons aged 50 and older as a target group for
vaccination against herpes zoster, pneumococcal disease
and pertussis. Their report considered vaccination for
hepatitis A to be universal [10].
Beyond the Netherlands and Europe, the consensus in
the United States is that these four vaccines are
important throughout life. Vaccination for herpes zoster
is recommended from the age of 60 and for pneumococ-
cal disease from 65 by the Advisory Committee on
Immunization Practices (ACIP) of the Centers for Disease
Control and Prevention. Furthermore, a combined vaccineAvailability
Effectiveness
Adverse events









Figure 1 Considerations in adapting the national immunization progrfor tetanus, diphtheria and pertussis is recommended every
10 years. For hepatitis A, two doses in a lifetime are
recommended when any risk factor is present [11].
Methods
Evaluation model
Vaccines against herpes zoster, pneumococcal disease,
pertussis and hepatitis A were reviewed according to
the criteria for adding new vaccines to the national
immunization programme [9]. These criteria help in
collecting relevant scientific information necessary for
evaluation and decision making. The four domains of
the model (pathogen, vaccine [as proposed by Kimman
et al.], disease and cost-effectiveness) are presented as
crucial elements of an adapted national immunization
programme (Figure 1).
Data source
To determine the incidence of herpes zoster during
1998–2009, information was assembled from the
Continuous Morbidity Registration (CMR: 1998–2001)
and the Netherlands Information Network of General
Practices (LINH: 2002–2009), as well as the Dutch
Institute for Health Services Research (NIVEL). The
CMR and LINH are nationally representative networks
of general practitioners (GP’s) that report the incidence
of infectious diseases weekly.
We determined via notifications the incidence of
pertussis since 1975 and hepatitis A since 1950 [12]. The
incidence of invasive pneumococcal disease was based
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surveillance system that collects nationwide pneumococ-
cal isolates from blood and cerebrospinal fluid” and
represents 25% of the Dutch population [13].
Information on hospital admissions for pertussis and
herpes zoster was drawn from the National Medical
Registration. Registration coverage of this system fluctu-
ates around 90%. Mortality rates were obtained from
Statistics Netherlands, which registers mortality data
from death certificates on a statutory basis. Seropreva-
lence data to estimate prevalences of varicella zoster,
pertussis and hepatitis A were available from two cross-
sectional, population-based serosurveillance studies car-
ried out in 1995–1996 and 2006–2007 among persons
aged 0 to 79 years [14,15]. The international literature
was searched for additional information on the four do-
mains of the evaluation model for each of the infectious




Nearly 100% of the Dutch population is seropositive for
varicella zoster virus and thus at risk for the later devel-
opment of herpes zoster [16]. The occurrence of herpes
zoster and its recurrence is also elevated in persons with
an immune deficiency [17].
For pneumococcal disease, the different serotypes vary
in virulence, invasiveness and their potential to colonize.
Of the more than 90 identified pneumococci serotypes,
about 20% are responsible for more than 70% of the
cases of invasive pneumococcal disease in all age groups
[18]. By age, the incidence of invasive pneumococcal
disease displays a parabolic pattern; the incidence is
highest in children and persons aged 60 and older [19].
Nasopharyngeal carriage of Streptococcus pneumoniae
was found to be low in non-institutionalized older
persons (aged 65 and older) [20]. However, for certain
serotypes, carriage was higher in older persons with
much exposure to children compared to older persons
with no exposure to children [20].
For pertussis, the incidence among persons aged 50
and older is rising. In 2006–2007 the reported incidence
in persons aged 50 to 64 years old was 6 times higher
than it was in 1995–1996, and the incidence was 8 times
higher in those aged 65 to 79 years old in 2006–2007
compared to 1995–1996 [21]. Serological studies showed
that between 6000 and 8000 per 100,000 persons aged
50 to 60 years and between 4000 and 6000 per 100,000
persons aged 60 to 79 years showed evidence of a recent
(< 6 months) pertussis infection [22]. Pertussis is often
atypical in adults. In the Netherlands, only 17% of per-
sons 50 to 64 years old and 36% of those aged 65 to
79 years old who showed serological evidence of arecent pertussis infection had reported coughing in
2006–2007 [21].
For hepatitis A, it was estimated in 2012 that in the
next 10 years 60% of the population 60 and older may
be susceptible to that disease in the absence of vaccin-
ation or natural exposure [23]. Meanwhile, the average
age of individuals who become infected is rising. Also in
2012, 12% of the participants in a seroprevalence study
had been vaccinated against hepatitis A owing to travel.
Because such a vaccination induces possible lifelong
immunity, this group could be considered protected
against hepatitis A even as they age [15]. The course of
infection is more severe in persons aged 50 and older,
and patients with chronic hepatitis B and C infections
are at risk of more severe disease if they contract
hepatitis A [24].
Infectiveness and transmissibility
Herpes zoster is the result of a reactivation of the dor-
mant varicella-zoster virus in the central nervous system
due to a diminished cell-mediated immunity. The vesicle
rash specific to herpes zoster is contagious for non-
immune persons until the vesicles have crusted; trans-
mission occurs sporadically [25].
The transmission of pneumococci and pertussis is air-
borne, and both pathogens are contagious. Pneumococci
are transmitted by nasopharyngeal carriers [26]. The
infectiveness and transmissibility of pertussis is probably
related to coughing, which makes pertussis highly conta-
gious [27,28]. During an outbreak of pertussis in a Dutch
religious institution, the attack ratio was 42% among the
elderly [29].
Hepatitis A is transmitted by the fecal-oral route, by
person-to-person contact or by ingestion of contami-
nated food or water [24]. Hepatitis A is also highly con-
tagious due to the long survival period of the virus in
the feces [24]. Community outbreaks in Latvia, Slovakia
and in the Czech Republic showed a low attack rate
among the elderly population [30-32]. To date, no
outbreaks of hepatitis A have been reported among the
elderly population in the Netherlands [33]. However,
with the changing immunity profiles in the elderly popu-
lation reflecting a decline in natural infection due to
improved hygiene, these attack rates are expected to be
higher in the future because of the diminishing of
natural immunity.
Antigenic variation
Varicella zoster and hepatitis A are stable viruses. Whereas
several genetic variations exist, all belong to the same
known serotype [34,35]. However, many different serotypes
of pneumococci are associated with invasive disease. A
phenomenon called serotype replacement has been seen
after routine pneumococcal vaccination: although herd-
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implementation of the 7-valent conjugate pneumococcal
vaccine (PCV-7) for children, there has been a rise in
pneumococcal disease in the study population. Its higher
incidence is caused by non-vaccine PCV-7 serotypes. The
serotype replacement depends on age, geographic region
and the development of antibiotic resistance [18]. Similarly,
for pertussis there is evidence that antigenic changes have
occurred as a result of mass vaccination [36].
Disease
Burden of disease
Herpes zoster, pneumococcal disease and pertussis are
highly prevalent among persons aged 50 and older in the
Netherlands [16,19,22,37]. Herpes zoster will develop in
about 23% to 30% of the European population [38]. It
causes a painful and itchy rash that proceeds to
postherpetic neuralgia (PHN) in 9% to 34% of the elderly
population who have the disease [39]. The pain associated
with the rash and PHN is neuropathic and therefore less
sensitive to painkillers, and there are no effective treatment
options [40]. In the Netherlands, on average per year,
717 per 100,000 persons aged 50 and older consult a
general practitioner because of herpes zoster, and 9.4
per 100,000 are admitted to the hospital. The number
of hospital days increases with age. Herpes zoster has
been reported to lead to a decrease in quality of life
(health-related quality of life, HRQoL), with an impact
on the activities of daily living (ADL) [41-44]. The total
number of quality-adjusted life years (QALYs) lost be-
cause of herpes zoster has varied between 1060 and
3024 for persons aged 60 to 80 years [45].
Pneumococcal disease can lead to various clinical syn-
dromes in older persons, such as invasive pneumonia
(the most common), bacteraemia and meningitis [19].































Figure 2 Notifications for pertussis from 2000 to 2011 for persons ag
number of notifications of pertussis per 100.000 persons 50 years and oldedisease is 54 per 100,000 persons aged 50 and older. For
pneumonia, the incidence in general practice has been
established at 17.5 per 1,000 patients aged 65 to 74 old
and 31.4 per 1,000 patients aged 75 and older [46].
However, this overview included all causes of pneumo-
nia, not just pneumococcal infection. It has been esti-
mated that 30% to 40% of all pneumonia cases are
caused by pneumococcal infection [47]. On average, 590
per 100,000 persons aged 50 and older are admitted to
the hospital yearly for pneumococcal disease. The num-
ber of admissions to the intensive care unit are highest
for meningitis, with 58% for persons aged both 50 to
64 years old and 65 and older, and lowest for bacter-
aemia, with 18% for both age groups. The average dur-
ation of a hospital admission was reported to be 13 days.
Bacteraemia and meningitis were associated with the
highest fatality rates, 40% and 39%, respectively, for per-
sons aged 65 and older [19]. It is estimated that 648
QALYs are lost due to pneumococcal disease in the eld-
erly population [48].
Pertussis causes symptoms similar to a common cold,
but it can also lead to a prolonged chronic paroxysmal
cough [39]. From 2004 on, a rise in the number of notifi-
cations has been observed for persons 50 aged and older
(Figure 2). From 2002 to 2005, 4,963 cases were reported
among persons aged 45 and older. In the same period,
10,338 GP consultations and 28 hospital admissions
were reported among persons aged 45 and older [49].
Figure 2 shows an increase in the notifications of pertus-
sis for persons aged 50 and older in 2000–2011. The
complications of pertussis reported in adults are urinary
incontinence, pneumonia, rib fractures, fainting, sinusitis
and otitis media [50]. A pertussis outbreak in a monas-
tery in the Netherlands showed the potential severity of
the impact in the deaths of 4 persons aged 55 and older
[29]. Pertussis also has an impact on the ADL [44]. We2006 2007 2008 2009 2010 2011
notification
ed 50 years and older. The dots on the black line represent the
r for 2001 to 2012.
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represent a loss of 50 and 25 QALYs, respectively.a
Hepatitis A causes jaundice, nausea, fever and infec-
tion; very rarely it can lead to liver failure [24]. The
severity increases with age, leading to a higher number
of hospitalizations and to longer hospital stays [33]. The
case fatality rate in persons aged 50 and older was
reported to be 1.8% [51]. In total, 436 cases were
reported among persons aged 50 and older from 2003
until May 2012. On average, the disease burden, as
expressed in disability-adjusted life-years (DALYs), for all
patients with notified cases of hepatitis A was estimated
at 17 for 2005–2010 [33].
Use and cost of healthcare
Most of the cost of healthcare for the diseases under
review is due to GP visits, hospital admissions, labora-
tory tests and medication such as antiviral medication
for herpes zoster and antibiotics for pertussis and
pneumococcal disease. For hepatitis A, there is no cure,
but the symptoms can be controlled; additional expense
is incurred to vaccinate the close contacts of those with
hepatitis A.
For herpes zoster, it is estimated that the total cost in
the Netherlands for GP consultations and drugs is
€72.05 per case and €101.10 per case of PHN [45]. For
pneumococcal disease, it is estimated that the mean
direct cost per case (meaning the direct medical costs
as registered by the Statistics Netherlands [CBS]),
depending on the outcome of the infection, can vary
from €17.10 (pneumonia requiring GP consultation) to
€15,255.00 (meningitis). The mean indirect cost (mean-
ing indirect costs of productivity losses registered by the
CBS) per case varies from €6.50 (pneumonia requiring
GP consultation) to €302.00 (meningitis) [48] (Table 1).
For pertussis, it is estimated that the cost of healthcare
was €75 per case for persons aged 45 and older in the
Netherlands from 2002–2005. The largest contributing
expenses were GP consultations and laboratory diagnostics
[49]. For hepatitis A, no studies have been conducted on
costs associated with the study population. The cost per
patient, with an average age of 30 years, has been estimated
at €1,579 [33].Table 1 Use and costs of healthcare for pneumococcal diseas
Healthcare c
Disease outcome Mean direct
Meningitis € 15,255.00
Pneumonia requiring GP consultation € 17.10
Pneumonia requiring hospitalization € 5,194.00
Bacteraemia € 8,077.00
a The main direct and indirect costs were calculated by taking the age-related resou
and indirect costs of productivity losses registered by the Statistics Netherlands (//sWork absenteeism
The cost of absence from work is a growing concern in this
age group. According to the CBS, 45% of the persons aged
55 to 65 years old were working in 2008. However, the pro-
portion of persons who continue working has increased
during recent years and will continue to grow [52].
Becoming infected while employed can lead to an em-
ployee’s loss of productivity. A study to estimate the prod-
uctivity loss related to herpes zoster calculated that 64% of
the persons aged 50 and older who had a job when they
contracted the disease missed on average 43 hours of
work; 76% reported on average 34 hours of decreased ef-
fectiveness [53]. For hepatitis A, the incidence is too low
to account for lost productivity; no data on productivity
loss was found for the other infectious diseases.
Alternative preventive measures
No alternative measures are known to prevent herpes
zoster, pneumococcal disease or pertussis; only vaccin-
ation is effective. Practicing basic hygiene is important
for preventing hepatitis A infection because of its fecal-
oral transmission route, and post-exposure vaccination
of patients’ close contacts has also proved effective in
preventing hepatitis A [54].
Vaccine
Availability of vaccines
The European organization for the registration of vac-
cines in Europe is the European Medicine Agency
(EMA; http://www.ema.europa.eu/ema/).
Vaccines are available for herpes zoster, pneumococcal
disease, pertussis and hepatitis A. Both Zostavax (for
prevention of herpes zoster) and Prevenar13 (for preven-
tion of pneumococcal disease) are registered in Europe
for persons aged 50 and older. Pneumo23 is used in
high-risk groups in the Netherlands [55]. Boostrix has
been registered as a booster combination vaccine (DTaP-
IPV) for the prevention of diphtheria (D), tetanus (T),
pertussis (aP) and polio (IPV). Epaxal, Avarim and
Havrix have been registered for the prevention of hepa-
titis A. The vaccines to prevent pertussis and hepatitis A
have been licensed in Europe for the general adult
population, not especially for the elderly population,e by disease outcome per case [48]
osts





rce information published in Jansen et al. [19] and the direct medical costs
tatline.cbs.nl, in Dutch).
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States, Boostrix was recently approved for use in persons
aged 65 and older [56].
Effectiveness
Zostavax has reduced the burden of herpes zoster by
61.1%, the incidence of PHN by 66.5% and the incidence
of herpes zoster by 51.3%. These results were observed
in persons aged 60 and older during five years of follow-
up [57]. This vaccine’s effectiveness against herpes zoster
was less in persons aged 70 and older than in those aged
60 to 69 years. The prevention of PHN was not
age-dependent [57] (Figure 3). Vaccination has also been
shown to reduce the negative impact of herpes zoster on
the daily activities of persons aged 60 and older [58].
A single shot was found to confer protection for ap-
proximately six years, but more research on the duration
of protection is needed [59].
Currently, a randomized controlled trial (RCT) is being
performed to determine the effectiveness of Prevenar13
(a 13-valent conjugated vaccine) among persons aged 65
and older in the Netherlands [60]. This vaccine includes
65% to 77% of the serotypes responsible for invasive
pneumococcal disease in Europe, whereas Pneumo23
covers 81% to 91% of the serotypes causing the disease in
European adults [18]. Strong evidence of efficacy of a
pneumococcal polysaccharide vaccine like Pneumo23
against invasive pneumococcal disease has been found, but
the antibody levels in persons aged 65 and older seem to
decline in three to five years [61,62].
Data are lacking on the effectiveness of pertussis vac-
cination in persons aged 50 and older. The risk ofFigure 3 The effectiveness of Zostavax for preventing HZ,
burden of illness and PHN among different age groups [38].
The light grey bar represents the vaccine effectiveness on the
incidence of herpes zoster, the burden of illness and postherpetic
neuralgia of the total study population. The white bar represents the
vaccine effectiveness on the incidence of herpes zoster, the burden
of illness and postherpetic neuralgia for those aged 60–69 years. The
dark grey bar represents the vaccine effectiveness on the incidence
of herpes zoster, the burden of illness and postherpetic neuralgia for
those 70 years and older.pertussis was reduced by 92% in patients aged 15 to
65 years old after acellular pertussis vaccination [63,64].
Since a single dose of Boostrix induced an effective im-
mune humoral response against pertussis, it is likely to
protect persons aged 55 and older. However, the im-
munogenicity in persons aged 75 and older was not clear
because of the low number of subjects in the study [65].
Immunity in children after vaccination wanes within
several years. This implies that one dose might lead to
reduced transmission, but not to long-term individual
protection [66]. Booster vaccinations may therefore be
necessary.
One study was conducted on the immunogenicity of the
hepatitis A vaccine in persons aged 50 and older. In this
prospective uncontrolled study, an effective immune re-
sponse was induced after two doses, achieving a protection
of 98% [67]. Antibodies remain in vaccinated adults for 12
to 25 years, but their presence is potentially lifelong [68].Adverse events, safety considerations
Adverse events following vaccination against herpes
zoster, pneumococcal disease, pertussis and hepatitis A
are commonly mild and self-limiting. More serious and
long-term complications are rare (reported by http://
www.fk.cvz.nl/).
Herpes zoster vaccine is contraindicated in persons
with a hypersensitivity (allergy) to an active substance,
immune deficiency, or untreated active tuberculosis or
those who are being treated with immune suppressors
or high doses of corticosteroids. The pneumococcal vac-
cine is contraindicated in people who are hypersensitive
to the active substances, to any of the other ingredients
or to diphtheria toxoid. People who have a high fever
should not receive the vaccine until they have recovered.
The pertussis vaccine is contraindicated in persons aged
50 and older who have an infectious disease at the time
of vaccination. Hepatitis A vaccine is contraindicated in
those who have a high fever as a consequence of disease,
and Epaxal must not be given to persons aged 50 and
older with a sensitivity to eggs and chicken protein.
Herpes zoster, 13-valent pneumococcal and pertussis
vaccine have been given concomitantly with influenza
vaccine and were well tolerated [69-71]. Boostrix has
also been given concomitantly with Havrix and was well
tolerated [72]. To achieve an optimal benefit, pneumo-
coccal vaccination and herpes zoster vaccination must
be given four weeks apart [73].Costs of the vaccine and the vaccination programme
Market prices for the vaccines range from €14.98
(Pneumo 23) to €137.33 (Zostavax) [74]. The prices are
likely to be lower when the products are used in a
vaccination programme. In addition, the number and
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tion will influence the costs of a vaccination programme.
The estimated cost of implementing a vaccination
programme, including administration costs, in the
Netherlands for herpes zoster within the current influ-
enza programme ranges from roughly €14.7 million for
persons aged 60 and older to €4.9 million for persons aged
80 and older (assuming an uptake of 75%). Furthermore,
once-only costs would be €0.3 million [45].
For hepatitis A, the costs of a vaccination programme,
including a catch-up programme for all persons aged 60
and older performed by general practitioners, would be
€210 million in the first year and €13 million in subsequent
years (indexed for 2009 for all persons aged 60 and older).
We estimated the annual costs of pertussis (with
Boostrix) and pneumococcal vaccination (with Prevenar13),
assuming an uptake of 75% among persons aged 60 and
older and at the retail price.b For pertussis vaccination, an
indication of the annual costs would be €65 million; for
pneumococcal vaccination, it would be €190 million. This
estimate does not include additional costs, such as the
fee for general practitioners or the potential need for
revaccinations.
Cost-effectiveness
A Dutch cost-effectiveness study found that herpes zoster
vaccination for persons aged 70 years old was marginally
cost-effective (€21,716 per QALY, based on the reduction
in burden of disease). Vaccination of other age groups was
not cost-effective owing to the vaccine’s cost and lack of
effectiveness [45].
The cost-effectiveness of the 13-valent pneumococcal
vaccine was demonstrated in different scenarios [48]. No
cost-effectiveness study is available on pertussis vaccination
of the study population. A world-wide review of economic
evaluations of booster vaccination against pertussis for
adults concluded that many studies were strongly affected
by the lack of reliable input data on real incidence and
by the number of unreported cases [75]. A study from
Germany concluded that vaccinating adults with a booster
vaccination (>18 years old) would be cost-effective when
the incidence is greater than 120 per 100,000 population
[76]. It was found unlikely that vaccination of the study
population against hepatitis A in the Netherlands would be
cost-effective due to the currently low incidence rates.
Moreover, most cases in the Netherlands are related to
travel, and an increasing number of persons are being
vaccinated against hepatitis A [23].
A summary of the results discussed above is given in
Table 2.
Discussion
We assessed herpes zoster, pneumococcal disease, per-
tussis and hepatitis A vaccines according to a previouslyformulated set of criteria for additions to a national
immunization programme. Herpes zoster, pneumococcal
disease and pertussis are common among persons aged
50 and older in the Netherlands, and in the future, this
study population will become more susceptible to hepa-
titis A, because fewer persons will have acquired natural
immunity through exposure. For each of these infectious
diseases, a vaccine is available, although its effectiveness
varies. Whereas vaccination might have consequences
for the virulence and prevalence of pneumococcal dis-
ease and pertussis, it could lower the disease burden and
reduce healthcare costs. Only vaccination against herpes
zoster and pneumococcal disease currently appear to be
cost-effective.
Routine vaccination in childhood has been extremely
successful in reducing the health burden, as shown in
numerous studies. Our review suggests that, although
vaccination can improve the health of persons aged 50
and older, the data, even on available vaccines, is still
far from sufficient to judge the full potential impact.
Besides, the vaccines against pertussis and hepatitis A
have not yet been registered for the study population
in Europe.
Vaccination against certain types of pathogens will
prevent mainly severe disease and death, such as in inva-
sive pneumococcal disease, where mortality is the main
concern. Vaccination against other types (with low case
fatality rates) will increase a person’s quality of life by
limiting functional loss, reducing frailty and preventing
the exacerbation of the underlying disease, such as in
herpes zoster and pertussis, where loss of quality of life
is most prominent [9]. The effect of vaccination can also
differ across age groups. For the herpes zoster vaccine,
persons aged 60 to 69 years profit more from a decrease
in the incidence of the disease and its burden than per-
sons aged 70 to 79 years. However, the effectiveness of
the vaccine in regard to the incidence of PHN hardly dif-
fers between persons aged 60 to 69 years and those aged
70 to 79 years.
Considering the incidence and the crude estimated bur-
den of the various diseases, prevention of pneumococcal
disease and herpes zoster might warrant higher priority
than prevention of pertussis and hepatitis A. The study
population will become more susceptible to hepatitis, yet
they might avoid it by being vaccinated for travel. This
protection is possibly life long, thereby making vaccination
of the study population against hepatitis less of a priority.
In the seroprevalence report of 2005–2006, already 23% of
the persons aged 0 to 79 years old had been vaccinated
against hepatitis A. For pertussis, however, there may be
much underreporting, which is suggested by the difference
between notifications and serological incidence, so the
burden of disease is unclear. Lack of information on the
disease burden makes it hard to compare pertussis to
Table 2 An overview of the model of Kimman et al. [9] for herpes zoster, pneumococcal disease, pertussis and hepatitis A
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http://www.biomedcentral.com/1471-2318/13/32influenza, which is already in the vaccination programme
for the study population in some European countries [7].
Vaccination of persons aged 50 or older is important,
considering immunosenescence and the fact that infec-
tions frequently lead to irreversible frailty and thereby to
more dependency after recovery [6]. Therefore, insight
into the optimal timing of vaccination is essential.
Vaccination at the age of 50, before immunosenescence
occurs, might provide increased protection [77]. For that
reason, we took 50 years old as the minimum age for
this review. Of note, the lowest age at which most
European countries offer influenza vaccination is 60.
Thus, a possible reduction of the age for access to the
influenza programme might be beneficial; that possibility
is being considered by the health council of the
Netherlands [78].
Furthermore, decisions on vaccination in childhood
should take into account the potential change in disease
dynamics in the study population and vice versa. For ex-
ample, routine vaccinations against varicella in children
could have implications for the occurrence of herpes
zoster in persons aged 50 and older [79].
Other questions remain about the effectiveness and
duration of protection of the candidate vaccines in the
study population. In one trial involving herpes zoster
vaccine, its efficacy was the lowest for persons aged 70
and older; this was the group with the highest incidence
and disease burden [57]. For pneumococcal disease,
clarification of the effectiveness of the 13-valent conju-
gated vaccine in persons aged 65 and older are pending
the results of an RCT [60]. Furthermore, questions re-
main about the number of doses needed to obtain an
optimal and lasting immune response and the necessity
of repeating the vaccination.
One of the major questions concerning potential
improvements through vaccination in the health of
persons aged 50 and older is whether they would
accept such an intervention. This population may
perceive the situation differently from younger individ-
uals. For example, in the United States, vaccination
against herpes zoster is recommended, but the uptake
is low in persons aged 60 and older [80]. Before the
implementation of new vaccination strategies for the
study population, it is of utmost importance to gain
more knowledge about acceptance of new vaccines, its
uptake and the determinants that influence the uptake.
Research should also address the preferences of the
study group with respect to the effects and implica-
tions of primary prevention for VPDs.
Conclusion
In conclusion, in the field of primary prevention for per-
sons aged 50 and older, vaccination against herpes zoster
and pneumococcal disease are potentially effective. Itshould be kept in mind that, although we have mainly
used Dutch data, certain aspects of vaccination are not
limited to a specific country. Therefore, we believe that
the results of this review are also relevant to other
Western European countries. More research would
ensure the best possible improvement in health for the
growing population of persons aged 50 and older.
Consent
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images.
Endnotes
aBased on cases reported in CMR during the period
2002–2005 and the weight estimates given by Lee et al.,
2007 (72).
bRetail price Boostrix: €23.29.
Retail Prevenar13: €67.72.
Assuming uptake of 75%: 3,700,000 × 0.75 = 2,800,000
persons aged 60 and older (Central Office for Statistics
Netherlands).
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